Skip to main content
SpringerLink
Log in

Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this study was to assess GH response to oral glucose tolerance test (OGTT) and TRH stimulation test in a group of 10 patients with active post-operative acromegaly before and after long-term slow-release (SR) lanreotide therapy (30 mg im every 10–14 days). Seven patients (2 males, 5 females, 29–71 yr), who during therapy maintained plasma GH and IGF-I concentrations under 5 μg/l and 450 μg/l, respectively, were considered as responders and studied for 24 (1 patient) to 36 months (6 patients). Three patients (1 male, 2 females, 46–61 yr) with levels of GH and IGF-I above those values were studied for 12 months. The OGTT (75 g po) and TRH test (400 μg iv) were repeated before and after 6, 12, 24 and 36 months. The GH response to OGTT was abnormal (nadir: >2 μg/l) at 6 and 12 months in poorly responsive patients. This response was normalized in all responsive patients. Nonetheless, 2 responsive patients showed abnormal GH values after OGTT once each throughout the 36-month study period. The GH response to TRH was characterized by great variability and exhibited unpredictable behavior throughout the study period both in responsive and in poorly responsive patients. Only 2 patients in the responsive group showed persistent normal GH levels (peak: ≤5 μg/l) after TRH for 3 yr. In conclusion, SR lanreotide treatment gave rise to a correct control of GH hypersecretion and to a normalization of GH response to oral glucose in 7 out of 10 patients, although it did not abolish the paradoxical reaction of GH to TRH in all responders. The effect of SR lanreotide on GH response to glucose tolerance test was not paralleled by GH response to TRH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bengtsson B.A., Edén S., Ernest I., Oden A., Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand. 1988, 223: 327–335.

    Article  CAS  PubMed  Google Scholar 

  2. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J. Clin. Endocrinol. Metab. 1995, 80: 3395–3402.

    CAS  PubMed  Google Scholar 

  3. Davis D.H., Laws E.R., Ilstrup D.M., Speed J.K., Caruso M., Shaw E.G., Abboud C.F., Scheithauer B.W., Root L.M., Schleck, C. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J. Neurosurg. 1993, 79: 70–75.

    Article  CAS  PubMed  Google Scholar 

  4. Eastman R.C., Gordon P., Glatstein E., Roth J. Radiation therapy of acromegaly. Endocrinol. Metab. Clin. North Am. 1992, 21: 693–712.

    CAS  PubMed  Google Scholar 

  5. Sassolas G., Harris A.G., James-Deidier A., French SMS 201–995 Acromegaly Study Group. Long-term effect of incremental doses of the somatostatin analog SMS 201–995 in 58 acromegalic patients. J. Clin. Endocrinol. Metab. 1990, 71: 391–397.

    Article  CAS  PubMed  Google Scholar 

  6. Ezzat S., Snyder P.J., Young W.F., Boyajy L.D., Newman C., Klibanski A., Molitch M.E., Boyd A.E., Sheeler L., Cook D.M., Malarkey W.B., Jackson I., Vance M.L., Thorner M.O., Barkan A., Frohman L.A., Melmed S. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann. Intern. Med. 1992, 117: 711–718.

    Article  CAS  PubMed  Google Scholar 

  7. Newman C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M.E., Gagel R.F., Boyd A.E., Sheeler L., Cook D., Malarkey W.B., Jackson I.M.D., Vance M.L., Thorner M.O., Ho P.J., Jaffe C.A., Frohman L.A., Kleinberg D.L. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. J. Clin. Endocrinol. Metab. 1995, 80: 2768–2775.

    CAS  PubMed  Google Scholar 

  8. Heron I., Thomas F., Dero M., Gancel A., Ruiz J.M., Shatz B., Kuhn J.M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 1993, 76: 721–727.

    CAS  PubMed  Google Scholar 

  9. Morange I., De Boisvilliers F., Chanson P., Lucas B., Dewailly D., Catus F., Thomas F., Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. 1994, 79: 145–151.

    CAS  PubMed  Google Scholar 

  10. Giusti M., Gussoni G., Cuttica C.M., Giordano G., Italian Multicenter Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian Multicenter Study. J. Clin. Endocrinol. Metab. 1996, 81: 2089–2097.

    CAS  PubMed  Google Scholar 

  11. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201–995). Eur. J. Endocrinol. 1995, 132: 320–325.

    Article  CAS  PubMed  Google Scholar 

  12. Caron P., Morange-Ramos I., Cogne M., Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 1997, 82: 18–22.

    CAS  PubMed  Google Scholar 

  13. Rajassorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertso H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf.) 1994, 41: 95–102.

    Article  Google Scholar 

  14. Johnson M.R., Chowdrey H.S., Thomas F., Grint C., Lightman S.L. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur. J. Endocrinol. 1994, 130: 229–234.

    Article  CAS  PubMed  Google Scholar 

  15. Díez J.J., Iglesias P.L., Sastre J., Gómez-Pan A., Selgas R., Martínez-Ara J., Miguel J.L., Méndez J. Influence of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in uremic patients. Kidney Int. 1994, 46: 1387–1391.

    Article  PubMed  Google Scholar 

  16. Marek J., Hána V., Krsek M., Justová V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 1994, 131: 20–26.

    Article  CAS  PubMed  Google Scholar 

  17. Al-Maskari M., Gebble J., Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin. Endocrinol. (Oxf.) 1996, 45: 415–421.

    Article  CAS  Google Scholar 

  18. Giusti M., Ciccarelli E., Dallabonanza D., Delitala G., Faglia G., Liuzzi A., Gussoni G., Giordano Disem G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur. J. Clin. Invest. 1997, 27: 277–284.

    Article  CAS  PubMed  Google Scholar 

  19. Colao A., Marzullo P., Ferrone D., Marino V., Pivonello R., Di Somma C., Di Sarno A., Giaccio A., Lombardi G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J. Endocrinol. Invest. 1999, 22: 40–47.

    Article  CAS  PubMed  Google Scholar 

  20. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study. Eur. J. Endocrinol. 1995, 133: 430–439.

    Article  CAS  PubMed  Google Scholar 

  21. Reubi J.C., Landolt A.M. The growth hormone response to octreotide in acromegaly correlate with adenoma sandostatin receptors. J. Clin. Endocrinol. Metab. 1989, 58: 844–850.

    Article  Google Scholar 

  22. Kuhn J.M., Basin C., Mollard M., De Rouge B., Schatz B., Wolf L.M. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur. J. Clin. Invest. 1992, 22: 793–799.

    Article  CAS  PubMed  Google Scholar 

  23. Ohbu S., Yoshioka N., Honda M., Andoh Y., Sato Y., Takao N., Fukuda H., Wakayama Y. TRH stimulation test in healthy elderly: paradoxical response of growth hormone is abnormal in normal aging. Intern. Med. 1995, 34: 148–152.

    Article  CAS  PubMed  Google Scholar 

  24. Faglia G., Beck-Peccoz P., Ferrari C., Travaglini P., Ambrosi B., Spada A. Plasma growth hormone release to thyrotropin releasing hormone in patients with active acromegaly. J. Clin. Endocrinol. Metab. 1973, 36: 1259–1262.

    Article  CAS  PubMed  Google Scholar 

  25. Szabo M. TRH and GRF stimulate release of growth hormone through different mechanism. Am. J. Physiol. 1986, 250: E512–E517.

    CAS  PubMed  Google Scholar 

  26. Panerai A.E., Gil-Ad I., Cocchi D., Locatelli V., Rossi G.L., Müller E.E. Thyrotropin-releasing hormone-induced growth hormone and prolactin release: physiological studies in intact rats and hypophysectomized rats bearing an ectopic pituitary gland. J. Endocrinol. 1997, 72: 301–311.

    Article  Google Scholar 

  27. Ho K.K.Y., Weissberger A.J. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin. Endocrinol. (Oxf.) 1994, 41: 75–83.

    Article  CAS  Google Scholar 

  28. Ezzat S., Redelmeier D.A., Gnehm M., Harris A.G. A prospective multicenter octreotide dose response study in the treatment of acromegaly. J. Endocrinol. Invest. 1995, 18: 364–369.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Hospital La Paz, Téllez 8, 4R, 28007, Madrid, Spain

    Juan J. Díez, P. Iglesias & A. Gómez-Pan

Authors
  1. Juan J. Díez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Gómez-Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan J. Díez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Díez, J.J., Iglesias, P. & Gómez-Pan, A. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. J Endocrinol Invest 24, 303–309 (2001). https://doi.org/10.1007/BF03343865

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343865

Key-words

Search

Navigation